PIK3CB and triple-negative breast carcinoma: Furthermore, given the variable efficacy of targeting the PI3K pathway to date in unselected or PI3K-activated triple-negative breast cancer, additional biomarker analyses are needed to better understand the putative oncogenic role of these genes in this breast cancer subtype.